About: retinalconsultantsaz.com

Posts by retinalconsultantsaz.com:

Pravin U. Dugel, MD: Patient-Reported Visual Function from Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion, Including Macular Hole (Oasis) Study

In Brief: Symptomatic vitreomacular adhesion is associated with reduced visual acuity, which can significantly affect quality of life. This study was a prespecified analysis of the 2-year, sham-controlled OASIS trial. Clinically meaningful (≥5-point) changes in patient-reported outcomes were assessed. Ocriplasmin resulted in clinically meaningful improvements in visual function. Purpose: To evaluate patient-reported visual function after ocriplasmin… Read More »



Pravin U. Dugel MD: 1,800 Seconds™ in Advances in the Management of Age-Related Macular Degeneration

EARN CREDIT NOW Course Director: Pravin U. Dugel, MD Release Date: March 31, 2019 Expiration Date: March 31, 2020 Credits Available: Physicians – maximum of 0.5 AMA PRA Category 1 Credits™ Jointly provided by Postgraduate Institute for Medicine and Catamount Medical Education Supported by an independent educational grant from Novartis Pharmaceuticals Corporation Release Date: March… Read More »


Dr. Pravin U. Dugel: Oxurion NV Reports Positive Topline Phase 1 Results with THR-149

Oxurion NV Reports Positive Topline Phase 1 Results with THR-149, a novel, potent plasma kallikrein inhibitor for the treatment of DME Topline data show that THR-149 is well-tolerated and safe. No dose-limiting toxicities or drug-related serious adverse events reported. Rapid onset of action starting at Day 1 with increasing average improvement in Best Corrected Visual… Read More »


Pravin U. Dugel, MD: Clinical Effectiveness of Switching Between Ranibizumab and Aflibercept in Treatment of Neovascular AMD: US Real-World Outcomes

Purpose: The purpose of this article is to examine visual acuity (VA) outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes switching between ranibizumab and aflibercept in routine clinical practice. Methods: Electronic medical records were used to identify nAMD eyes receiving ranibizumab or aflibercept with 12 months’ follow-up since switching antivascular endothelial growth… Read More »


Dr. Pravin U. Dugel – HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration

Pravin U. Dugel, Adrian Koh, Yuichiro Ogura, Glenn Jaffe, Ursula Schmidt-Erfurth, David Brown, Andre V. Gomes, James Warburton, Andreas Weichselberger, Frank G. Holz Abstract ObjectiveTwo similarly designed, phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (AMD). DesignDouble-masked, multicenter, active-controlled, randomized trials. Patients(N = 1817) with untreated,… Read More »


Pravin Dugel, MD, joins Ross Lakhanpal, MD, to define, discuss, and forecast the future of informatics in retina. VBS 2019

Pravin Dugel, MD, R. Ross Lakhanpal, MD   Channels: Retina | Posted 4/5/2019 Pravin Dugel, MD, joins Ross Lakhanpal, MD, to define, discuss, and forecast the future of informatics in retina. In Dr. Dugel’s view, the informatics platforms used in other fields could translate to retina and, when they arrive, will change the preparation and… Read More »


Dr. Pravin U. Dugel Chairs Retina World Congress Unplugged

RWC Unplugged offers participants a unique opportunity to learn, share and discuss controversial topics in retina with a large group of industry experts and clinical leaders. With no scripts or industry commercials, this event evokes deep discussions moderated by KOLs, who encourage attendees to challenge their perspectives in lively, no-holds-barred discussions, with live polling on… Read More »


Positive preliminary data in US retinal trial: Significant improvement in vision in first cohort of Phase II subjects in US trial of hRPC cell therapy in retinitis pigmentosa

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with the ongoing Phase I/II clinical trial of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP). The Company is pleased to report that all three of the first… Read More »


Dr. Pravin U. Dugel Invited to Speak at First Gene Therapy for Chronic Retinal Diseases Summit in New York

ROCKVILLE, Md., Feb. 14, 2019 /PRNewswire/ — REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, will host an analyst and investor event focused on its ophthalmology program, including its lead product candidate RGX-314, on Thursday, February 21,… Read More »


© 2019 Retinal Consultants of Arizona. All Rights Reserved.
~ Design and Development by Advice Media | MedNet